PegBio's Diabetes Drug Completes First Batch of Prescriptions

MT Newswires Live07-22

PegBio (HKG:2565) said the first batch of commercial prescriptions of Paidakang has been issued at multiple medical institutions, according to a Wednesday Hong Kong bourse filing.

Ji Linong and Zhou Zhiguang issued the first respective prescriptions at Peking University People's Hospital and Second Xiangya Hospital of Central South University.

Ji and Zhou were the leading experts of a phase III clinical study of Paidakang, which is used for the treatment of type 2 diabetes in adults.

Following the prescriptions, Tenry Pharmaceutical, which had entered into a commercialization collaboration agreement with the company, is due to satisfy a second royalty payment.

Tenry Pharmaceutical has confirmed it will pay around HK$49 million in royalty to the biopharmaceutical company under the contract.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2653763372?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 21:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653763372","market":"hk","top_or_hot":-1,"title":"PegBio's Diabetes Drug Completes First Batch of Prescriptions","media":"MT Newswires Live","content":"<html><body><p> PegBio (HKG:2565) said the first batch of commercial prescriptions of Paidakang has been issued at multiple medical institutions, according to a Wednesday Hong Kong bourse filing.</p><p>Ji Linong and Zhou Zhiguang issued the first respective prescriptions at Peking University People's Hospital and Second Xiangya Hospital of Central South University.</p><p>Ji and Zhou were the leading experts of a phase III clinical study of Paidakang, which is used for the treatment of type 2 diabetes in adults.</p><p>Following the prescriptions, Tenry Pharmaceutical, which had entered into a commercialization collaboration agreement with the company, is due to satisfy a second royalty payment.</p><p>Tenry Pharmaceutical has confirmed it will pay around HK$49 million in royalty to the biopharmaceutical company under the contract.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PegBio's Diabetes Drug Completes First Batch of Prescriptions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPegBio's Diabetes Drug Completes First Batch of Prescriptions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-22 21:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> PegBio (HKG:2565) said the first batch of commercial prescriptions of Paidakang has been issued at multiple medical institutions, according to a Wednesday Hong Kong bourse filing.</p><p>Ji Linong and Zhou Zhiguang issued the first respective prescriptions at Peking University People's Hospital and Second Xiangya Hospital of Central South University.</p><p>Ji and Zhou were the leading experts of a phase III clinical study of Paidakang, which is used for the treatment of type 2 diabetes in adults.</p><p>Following the prescriptions, Tenry Pharmaceutical, which had entered into a commercialization collaboration agreement with the company, is due to satisfy a second royalty payment.</p><p>Tenry Pharmaceutical has confirmed it will pay around HK$49 million in royalty to the biopharmaceutical company under the contract.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2653763372","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653763372","pubTimestamp":1784726047,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PegBio  said the first batch of commercial prescriptions of Paidakang has been issued at multiple medical institutions, according to a Wednesday Hong Kong bourse filing.Ji Linong and Zhou Zhiguang issued the first respective prescriptions at Peking University People's Hospital and Second Xiangya Hospital of Central South University.Ji and Zhou were the leading experts of a phase III clinical study of Paidakang, which is used for the treatment of type 2 diabetes in adults.Following the prescriptions, Tenry Pharmaceutical, which had entered into a commercialization collaboration agreement with the company, is due to satisfy a second royalty payment.Tenry Pharmaceutical has confirmed it will pay around HK$49 million in royalty to the biopharmaceutical company under the contract.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02565":"派格生物医药-B"},"translate_title":"PegBio糖尿病药物完成首批处方","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"PegBio (HKG:2565) said the first batch of commercial prescriptions of Paidakang has been issued at multiple medical institutions, according to a Wednesday Hong Kong bourse filing.Ji Linong and Zhou Zhiguang issued the first respective prescriptions at Peking University People's Hospital and Second Xiangya Hospital of Central South University.Ji and Zhou were the leading experts of a phase III clinical study of Paidakang, which is used for the treatment of type 2 diabetes in adults.Following the prescriptions, Tenry Pharmaceutical, which had entered into a commercialization collaboration agreement with the company, is due to satisfy a second royalty payment.Tenry Pharmaceutical has confirmed it will pay around HK$49 million in royalty to the biopharmaceutical company under the contract.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.0","shortVersion":"4.47.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653763372","isCrawlerRequest":true}